Jasper Therapeutics, Inc. - 8-K Filing
Jasper Therapeutics issued $30 million in contingent value rights (CVRs) to shareholders if FDA grants a Priority Review Voucher for briquilimab by December 31, 2028. (Items: 8.01 Other Events)
Tickers: $JSPR
More Regulatory news
- SusGlobal Energy Corp. - 10-Q Filing
- Ideal Power Inc. - 8-K Filing
- DIGI INTERNATIONAL INC - 8-K Filing
- ZeroStack Corp. - 8-K Filing
- Sound Point Meridian Capital, Inc. - 8-K Filing
- Boost Run Inc. - 8-K Filing
- INTERFACE INC - 8-K Filing
- Neonode Inc. - 10-Q Filing
- Virtuix Holdings Inc. - 8-K Filing
- Neonode Inc. - 8-K Filing